By Stephen Nakrosis
Shares of Cumberland Pharmaceuticals were trading higher in the after-hours market after the company said the Food and Drug Administration approved a supplemental new drug application for liver drug Acetadote.
After the bell Monday, the company's shares had risen 56%, trading at $1.93. Volume in the after-hours market surpassed 4.4 million shares.
The stock finished the regular session with a gain of less than 1%, closing at $1.24.
Acetadote is an intravenous formulation indicated to prevent or lessen liver injury after ingestion of potentially toxic quantities of acetaminophen, according to the company.
Each year, thousands of individuals in the U.S. experience accidental or intentional acetaminophen poisoning, leading to serious liver damage, the company said.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
December 09, 2024 17:36 ET (22:36 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。